Publikationer 2016

Ahlstrand I, Vaz S, Falkmer T, et al. Self-efficacy, and pain acceptance as mediators of the relationship between pain and performance of valued life activities in women and men with rheumatoid arthritis. Clin Rehabil. 2016 May 4

Ajeganova S, Humphreys JH, Verheul MK, et al. Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts.
Ann Rheum Dis. 2016 Nov;75(11):1924–1932.

Altawil R, Saevarsdottir S, Wedrén S, et al. Remaining Pain in Early Rheumatoid Arthritis Patients Treated with Methotrexate. Arthritis Care Res (Hoboken). 2016 Aug;68(8):1061–8.

Askling J, Berglind N, Franzen S, et al. How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimize their comparability, in five RA registries. Ann Rheum Dis. 2016 Oct;75(10):1789–96.

Bala SV, Samuelson K, Hagell P, et al. Living with persistent rheumatoid arthritis: a BARFOT study. J Clin Nurs. 2016 Dec 21

Bengtsson K, Jacobsson LT, Rydberg B, et al. Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study. BMC Musculoskelet Disord. 2016 Dec 12;17(1):499.

Demmelmaier I, Dufour AB, Nordgren B, et al. Trajectories of Physical Activity Over Two Years in Persons with Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016
Aug;68(8):1069–77

Eriksson K, Nise L, Kats A, et al. Prevalence of Periodontitis in Patients with Established Rheumatoid Arthritis: A Swedish Population Based Case-Control Study. PLoS One. 2016 May 20;11(5): e0155956

Eriksson JK, Wallman JK, Miller H, et al. Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish Trial. Arthritis Care Res (Hoboken). 2016 Dec;68(12):1758-1766

Exarchou S, Lie E, Lindström U, Askling J, et al. Mortality in ankylosing spondylitis: results from a nationwide population-based study. Ann Rheum Dis. 2016 Aug;75(8):1466–72

Frisell T, Hellgren K, Alfredsson L, et al. Familial aggregation of arthritis-related diseases in seropositive and seronegative rheumatoid arthritis: a register-based case-control study in Sweden. Ann Rheum Dis. 2016 Jan;75(1):183–9.

Frisell T, Saevarsdottir S, Askling J. Does a family history of RA influence the clinical presentation and treatment response in RA? Ann Rheum Dis. 2016 Jun;75(6):1120–5.

Hambardzumyan K, Bolce RJ, Saevarsdottir S, et al. Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial. RMD Open. 2016 Mar 1;2(1).

Hambardzumyan K, Saevarsdottir S, Forslind K, et al. A multi-biomarker disease activity score and the choice of second-line therapy in early rheumatoid arthritis after methotrexate failure. Arthritis Rheumatol. 2016 Dec 19.

Hellgren K, Dreyer L, Arkema EV, et al.; Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.
Ann Rheum Dis. 2017 Jan;76(1):105-111. Epub 2016 May 4.

Iannone F, Courvoisier DS, Gottenberg JE, et al. Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the ”pan-European registry collaboration for abatacept (PANABA). Clin Rheumatol. 2016 Dec 14

Jiang X, Askling J, Saevarsdottir S, et al. A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy – results from a Swedish cohort study. Arthritis Res Ther. 2016 Dec 3;18(1):288.

Jiang X, Källberg H, Chen Z, et al. An Immunochip-based interaction study of contrasting interaction effects with smoking in ACPA-positive versus ACPA-negative rheumatoid arthritis. Rheumatology (Oxford). 2016 Jan;55(1):149-55

Kastbom A, Forslind K, Ernestam S, et al. Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial. Ann Rheum Dis. 2016 Feb;75(2):356-61

Kharlamova N, Jiang X, Sherina N, et al. Antibodies to Porphyromonas gingivalis Indicate Interaction Between Oral Infection, Smoking, and Risk Genes in Rheumatoid Arthritis Etiology. Arthritis Rheumatol. 2016 Mar;68(3):604–13.

Lindström U, Exarchou S, Lie E, et al. Childhood hospitalisation with infections and later development of ankylosing spondylitis: a national case-control study. Arthritis Res Ther. 2016 Oct 22;18(1):240.

Lindström U, Forsblad-d’Elia H, Askling J, et al. Perinatal characteristics, older siblings, and risk of ankylosing spondylitis: a case-control study based on national registers. Arthritis Res Ther. 2016 Jan 19; 18:16

Ljung L, Rantapää-Dahlqvist S, Jacobsson LT, et al. Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. Ann Rheum Dis. 2016
Dec;75(12):2087-2094

Martinsson K, Johansson A, Kastbom A, et al. Immunoglobulin (Ig)G1 and IgG4 anti-cyclic citrullinated peptide (CCP) associate with shared epitope, whereas IgG2 anti-CCP associates with smoking in patients with recent-onset rheumatoid arthritis (the Swedish TIRA project). Clin Exp Immunol. 2016 Nov 17.

Mercer LK, Askling J, Raaschou P,et al. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Ann Rheum Dis. 2017 Feb;76(2):386-391. Epub 2016 Jun 15.

Michaud K, Berglind N, Franzén S, et al. Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease. Ann Rheum Dis. 2016 Oct;75(10):1797-805

Nelson EC, Dixon-Woods M, Batalden PB, et al. Patient focused registries can improve health, care, and science. BMJ. 2016 Jul 1;354: i3319.

Olofsson T, Johansson K, Eriksson JK, et al. Does disease activity at start of biologic therapy influence work-loss in RA patients? Rheumatology (Oxford). 2016 Apr;55(4):729–34

Raaschou P, Simard JF, Asker Hagelberg C, et al. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. BMJ. 2016 Jan 28;352: i262.

Reed E, Jiang X, Kharlamova N, et al. Antibodies to carbamylated α-enolase epitopes in rheumatoid arthritis also bind citrullinated epitopes and are largely indistinct from anti-citrullinated protein antibodies. Arthritis Res Ther. 2016 May 4;18(1):96

Svensson B, Andersson M, Forslind K, et al. Persistently active disease is common in patients with rheumatoid arthritis, particularly in women: a long-term inception cohort study. Scand J Rheumatol. 2016 Nov;45(6):448–455.

Wadström H, Frisell T, Sparén P, et al. Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden. Ann Rheum Dis. 2016 Jul;75(7):1272–8.

van Wesemael TJ, Ajeganova S, Humphreys J, et al. Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study. Arthritis Res Ther. 2016 Dec 1;18(1):285.

Östlund G, Thyberg I, Valtersson E, et al. The Use of Avoidance, Adjustment, Interaction, and Acceptance Strategies to Handle Participation Restrictions Among Swedish Men with Early Rheumatoid Arthritis. Musculoskeletal Care. 2016 Dec;14(4):206-218